

References

I-36

1. National Comprehensive Cancer Network. Clinical practice guidelines in oncology: Antiemesis. Version. 1.2019.
2. Sadaba B, Barrio A, Campanero M, et al. Randomized pharmacokinetic study comparing subcutaneous and intravenous palonosetron in cancer patients treated with platinum based chemotherapy. PlosOne. February 2014;9(2):e89747.
3. Candiotti K, Ahmed S, Cox D, et al. Palonosetron versus ondansetron as rescue medication for postoperative nausea and vomiting: a randomized, multicenter, open-label study. BMC Pharmacology and Toxicology. 2014,15:45.
4. Aloxi[®] (palonosetron HCl) injection for intravenous use [package insert]. Helsinn Therapeutics, Inc. Iselin, NJ. Revised 09/2018.
5. Gilmore J, Peacock N, Gu A, et al. Antiemetic guideline consistency and incidence of chemotherapy-induced nausea and vomiting in US community oncology practice: INSPIRE study. Journal of Oncology Practice. January 2014; 10(1):68-74.
6. P Hesketh, K Bohlke, G Lyman. Antiemetics: American Society of Clinical Oncology Focused Guideline Update. Journal of Clinical Oncology. November 2015.64.3635.
7. MICROMEDEX[®]SOLUTIONS Compendia. 2019. Palonosetron.
8. Clinical Pharmacology Compendia. [database online]. Tampa FL: Gold Standard, Inc. Palonosetron. 2019.
9. NCCN Drugs & Biologics Compendium[™]. Palonosetron. 2019. National Comprehensive Cancer Network (NCCN).
10. Bungo Saito, Hidetoshi Nakashima, Maasa Abe, et al. Efficacy of palonosetron to prevent delayed nausea and vomiting in non-Hodgkin's lymphoma patients undergoing repeated cycles of the CHOP regimen. Supportive Care in Cancer. 2018;26(1):269-274.
11. van der Vorst MJDL, Neefjes ECW, Konings IRHM, Verheul HMW. Prophylactic treatment for delayed chemotherapy-induced nausea and vomiting after non-AC based moderately emetogenic chemotherapy: a systematic review of randomized controlled trials. Supportive Care in Cancer. 2015;23(8):2499-2506
12. Mukhopadhyay S, Kwatra G, Alice K P, Badyal D. Role of olanzapine in chemotherapy-induced nausea and vomiting on platinum-based chemotherapy patients: a randomized controlled study. Supportive Care in Cancer. 2017;25(1):145-154.
13. Hayashi T, Shimokawa M, Miyoshi T, et al. A prospective, observational,

multicenter study on risk factors and prophylaxis for low emetic risk chemotherapy-induced nausea and vomiting. *Supportive Care in Cancer*. 2017;25(9):2707-2714.